RPID · Rapid Micro Biosystems, Inc.
Market Cap
$38.34M
Shares
50.16M
Volume · Oct 19
198.07K
Avg daily vol (3M)
256.2K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.77
Open$0.80
Day$0.76–0.81
52W close$0.76–4.68
Avg vol 30d303K
Short int854K · 1.7% float · 2.3d
Short vol56%
Last earningsAug 7, 2026
DataJul 2021–Oct 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 2 wks
filed Aug 7, 2026
call held Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$35.18M
Trailing 12 months
Net income (TTM)
−$51.20M
Trailing 12 months
Revenue growth YoY
+10.9%
Year over year
Operating margin
-141.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$4.45M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.3%
Year over year · more shares
Price change (1Y)
-74.0%
Trailing year
Short interest
1.7%
Latest settlement · 2.3 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 7, 2026
Q2 FY26
TL;DR. RPID reported Q2 revenue of $8.1M (+11% YoY) with record 15% gross margin, reaffirmed full-year 2026 revenue/placements/margin guidance, and raised full-year validation guidance to at least 27 systems.
Bullish
- + Q2 revenue of $8.1M grew 11% YoY and exceeded prior guidance
- + Reached milestone of 200th Growth Direct system placed globally
- + Delivered record 15% Q2 gross margin, up 11 percentage points YoY
- + Recurring revenue grew 14% YoY to $5M
- + Raised full-year 2026 validation guidance to at least 27 systems
- + Efficiency program expected to reduce expenses/cash usage by ~$1M in 2026 and ~$3M annually from 2027
Bearish
- − Product margin remained negative at -3% in Q2
- − Q2 net loss widened to $12.9M from $11.9M YoY
- − Adjusted EBITDA loss of $10.3M versus $10.1M YoY
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
−38%
below
RSI (14)
23
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−32%
trailing
6-month return
−69%
trailing
YTD return
−73%
this year
Relative strength
−76%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 34 funds reported for Sep 30 · net +35.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.70% of float · ▼ -9.2% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 3-yr range
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+3%
Y/Y
Free cash flow
$-31.9M
Balance sheet
$27.1M
net cash
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
11.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 7, 2026
Total revenue
· full year 2026
Maintained
$37M – $41M
May 13, 2026
$37M – $41M
changed to
Aug 7, 2026
$37M – $41M
prior FY $33.59M
midpoint +16.1% Y/Y
Gross margin
· full year 2026
20%
Service margin
· full year 2026
45% – 50%
Depreciation and amortization expense
· full year 2026
Maintained
$3M
May 13, 2026
$3M
changed to
Aug 7, 2026
$3M
Stock compensation expense
· full year 2026
Maintained
$5M
May 13, 2026
$5M
changed to
Aug 7, 2026
$5M
CapEx
· full year 2026
Lowered
$1M
May 13, 2026
$2M
changed to
Aug 7, 2026
$1M
Interest income
· full year 2026
Maintained
$1M
May 13, 2026
$1M
changed to
Aug 7, 2026
$1M
Interest expense
· full year 2026
Maintained
$2M
May 13, 2026
$2M
changed to
Aug 7, 2026
$2M
Total gross margin
· full year 2026
20%
Operating expenses
· full year 2026
Raised
$51M – $53M
May 13, 2026
$48M – $52M
changed to
Aug 7, 2026
$51M – $53M
Non-cash expenses
· full year 2026
Maintained
$8M
May 13, 2026
$8M
changed to
Aug 7, 2026
$8M
Prior guidance
period ended
· from the Earnings Call filed Aug 7, 2026
Revenue
· Q3 2026
at least $9.5M
Gross margin percentage
· Q3 2026
at least 20%
Guided vs delivered
· last 4 settled
Revenue
Q2
guided at least $7.7M
$8.05M
In line
Full year total revenue
full year 2025
guided at least $33M
$33.59M
In line
Total revenue
full year 2024
guided at least $27M
$28.05M
In line
Total revenue
full year 2023
guided at least $22M
$22.52M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
23
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 34 funds reported for Sep 30 · net +35.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.70% of float · ▼ -9.2% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $5
vs 200-day avg -67%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cumulative systems placed | 200 | Three Months Ended June 30, 2026 filing | — |
| Cumulative systems validated | 169 | Three Months Ended June 30, 2026 filing | — |
| Recurring revenue percentage of total revenue | 63% | second quarter 2026 | — |
| Systems placed in period | 4 | Three Months Ended June 30, 2026 filing | — |
| Systems validated in period | 9 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RPID
this stock
Rapid Micro Biosystems, Inc.
|
$38.34M | -73.3% | +19.7% | — | 1.7% |
|
ABT
Abbott Laboratories
|
$180.99B | -16.9% | +5.7% | 33.6 | 0.8% |
|
MDT
Medtronic plc
|
$121.20B | -3.4% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$113.02B | -15.2% | +11.2% | 30.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.16B | -52.8% | +12.5% | 18.2 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RPID | -12.0% | -31.5% | -68.6% | -24.9% | -73.3% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -10.5% | -30.6% | -76.3% | -25.4% | -85.7% |